Travere Therapeutics (TVTX) EPS (Weighted Average and Diluted) (2013 - 2026)
Travere Therapeutics (TVTX) reported EPS (Weighted Average and Diluted) of -$0.4 for Q1 2026, up 14.89% on a YoY basis from -$0.35 in Q1 2025, and down 60.0% quarter-over-quarter from -$0.25 in Q4 2025.
Travere Therapeutics (TVTX) EPS (Weighted Average and Diluted) (2013 - 2026) Analysis & Trends
Travere Therapeutics has reported EPS (Weighted Average and Diluted) for 14 years, with the latest figure at -$0.4 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 14.89% year-over-year to -$0.4; the trailing twelve-month figure through Mar 2026 stood at -$0.51 (up 81.65% YoY), and the FY2025 full-year result was -$0.57, up 86.0% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.4, down from -$0.25 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $1.97 in Q3 2023, with the low at -$1.76 in Q1 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.66 across 5 years, with a median of -$0.91 in 2024.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) surged 280.73% — and 2024, when it tumbled 135.53%.
- Travere Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.03 in 2022, then dropped by 12.62% to -$1.16 in 2023, then jumped by 39.66% to -$0.7 in 2024, then surged by 64.29% to -$0.25 in 2025, then tumbled by 60.0% to -$0.4 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.4 (Q1 2026), -$0.25 (Q4 2025), and $0.28 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | -0.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.40 |
| Dec 31, 2025 | -0.25 |
| Sep 30, 2025 | 0.28 |
| Jun 30, 2025 | -0.14 |
| Mar 31, 2025 | -0.47 |
| Dec 31, 2024 | -0.70 |
| Sep 30, 2024 | -0.70 |
| Jun 30, 2024 | -0.91 |
| Mar 31, 2024 | -1.76 |
| Dec 31, 2023 | -1.16 |
| Sep 30, 2023 | 1.97 |
| Jun 30, 2023 | -1.13 |
| Mar 31, 2023 | -1.42 |
| Dec 31, 2022 | -1.03 |
| Sep 30, 2022 | -1.09 |
| Jun 30, 2022 | -1.05 |
| Mar 31, 2022 | -1.20 |
| Dec 31, 2021 | -0.84 |
| Sep 30, 2021 | -0.59 |
| Jun 30, 2021 | -0.64 |